Ismael Lares-Asseff | Pharmacology | Lifetime achievement Award


Warning: Undefined variable $insensitive in /home/u792129758/domains/sciencefather.com/public_html/academicawards/wp-content/plugins/internal-link-building-plugin/internal_link_building.php on line 201

Warning: Undefined variable $insensitive in /home/u792129758/domains/sciencefather.com/public_html/academicawards/wp-content/plugins/internal-link-building-plugin/internal_link_building.php on line 202

Assoc. Prof. Dr. Ismael Lares-Asseff | Pharmacology | Lifetime achievement Award

Assoc. Prof. Dr. Ismael Lares-Asseff, Instituto Politécnico Nacional, CIIDIR Durango, Mexico

Dr. Ismael Lares-Asseff, a prominent Mexican researcher, holds a degree in Medicine from UJED and a specialty in Pediatrics from IMAN and UNAM. He earned his Master’s and Ph.D. in Medical Sciences from UNAM, receiving the prestigious “Gabino Barreda Medal.” Mentored by renowned researcher Dr. Joaquín Cravioto, Dr. Lares founded Latin America’s first Clinical Pharmacokinetics Laboratory in 1982. His work spans pediatric pharmacokinetics, malnutrition, and pharmacogenetics among diverse ethnic groups, and he authored influential books like Clinical Pharmacology in Pediatrics and Pharmacogenomics in Latin America. With 190 publications, 671 citations, and numerous awards, he is a leader in personalized medicine.

 

Publication Profile

Scopus

Orcid

Background and Academic Achievements

Assoc. Prof. Dr. Ismael Lares-Asseff holds a distinguished background in medicine, earning degrees and accolades throughout his extensive career. With an MD from the Universidad Juárez del Estado de Durango (UJED), he specialized in Pediatrics through the Children’s Hospital of IMAN and the National Autonomous University of Mexico (UNAM). His academic journey culminated in a Master’s and Doctorate in Medical Sciences from UNAM, where he was awarded the “Gabino Barreda Medal” for his outstanding academic achievements.

Contributions to Pediatric Research and Clinical Pharmacokinetics

Under the mentorship of Dr. Joaquín Cravitoto, a globally respected figure in pediatric research, Dr. Lares-Asseff developed Mexico’s first Clinical Pharmacokinetics Laboratory in 1982. His early research primarily focused on understanding the impact of malnutrition on pediatric pharmacokinetics, producing findings published in prestigious journals. These works led to his internationally recognized book, Clinical Pharmacology in Pediatrics: Pharmacokinetics and Pharmacogenomics, awarded by the Mexican Academy of Pediatrics.

Conclusion

Assoc. Prof. Dr. Ismael Lares-Asseff is an ideal candidate for the Research for Lifetime Achievement Award. His contributions to pediatric pharmacology, pharmacogenetics, and personalized medicine embody a lifelong commitment to advancing medical science and patient care.

 

Publication Top Notes

  • 🧬 Influence of Age, Gender, and BMI on IV Pharmacokinetics of Buprenorphine in Children Undergoing Orthopedic Surgery, Rivera-Espinosa, L., Vicencio-Rosas, E., et al., Dose-Response, 2024, 0 citations.
  • 👨‍⚕️ Population Pharmacokinetics and Pharmacodynamics of L-asparaginase and Its Impact on Pancreatitis in Leukemia Patients, Gándara-Mireles, J.A., Lares-Asseff, I., et al., Drug and Chemical Toxicology, 2024, 0 citations.
  • 💉 Nutritional Status as a Risk Factor for Doxorubicin Cardiotoxicity in Mexican Children with ALL, Gándara-Mireles, J.A., Lares-Asseff, I., et al., Nutrition and Cancer, 2024, 0 citations.
  • 🧪 Impact of SNPs and Nutrition on Doxorubicin Pharmacokinetics and Cardiotoxicity in Leukemia Patients, Gándara-Mireles, J.A., Lares-Asseff, I., et al., Journal of Oncology Pharmacy Practice, 2023, 3 citations.
  • 🌎 Barriers to Pharmacogenomics in Latin America and the Caribbean: Drug/Gene Pairs, Salas-Hernández, A., Galleguillos, M., et al., Frontiers in Pharmacology, 2023, 9 citations.
  • 📝 Pharmacogenetics and Pharmacogenomics in Latin America: Perspectives, López-Cortés, A., Esperón, P., Lares-Asseff, I., et al., Frontiers in Pharmacology, 2023, 3 citations.
  • 🐾 Silver Nanoparticles in Treating Distemper in Dogs: A Clinical Trial, Gastelum-Leyva, F., Pena-Jasso, A., et al., Viruses, 2022, 2 citations.
  • 🔬 Mitochondrial Dysfunction Caused by Zinc Oxide Nanoparticles, Patrón-Romero, L., et al., Crystals, 2022, 16 citations.
  • 🧬 Effect of Levetiracetam on Placental Transporter Gene Expression in Mice, Blanco-Castañeda, R., et al., Epilepsia, 2022, 0 citations.
  • ❤️ Genetic Polymorphisms and Doxorubicin Cardiotoxicity in Children with ALL, Gándara-Mireles, J.A., Lares-Asseff, I., et al., Pharmacogenetics and Genomics, 2021, 8 citations.

 

 

 

Shubham Sharma | Pharmacology | Best Researcher Award


Warning: Undefined variable $insensitive in /home/u792129758/domains/sciencefather.com/public_html/academicawards/wp-content/plugins/internal-link-building-plugin/internal_link_building.php on line 201

Warning: Undefined variable $insensitive in /home/u792129758/domains/sciencefather.com/public_html/academicawards/wp-content/plugins/internal-link-building-plugin/internal_link_building.php on line 202

Shubham Sharma | Pharmacology | Best Researcher Award

Dr Shubham Sharma, Pfizer, United States

Dr. Shubham Sharma is a leading computational modeler with 8+ years of expertise in theoretical materials science, physics, and chemistry. Holding a Ph.D. in Chemical & Environmental Engineering from Brown University (2021), he specializes in atomistic modeling and solid-form design, notably working at Pfizer where he leads drug de-risking efforts. His research in catalysis, electrochemistry, and crystal structure predictions has earned him over 10 Pfizer Bravo awards. Dr. Sharma’s groundbreaking work is recognized globally, including invited talks at major conferences, advancing both pharmaceutical and renewable energy applications. 💻🔬💊⚡

Publication Profile

Google Scholar

Education

This individual holds a PhD in Chemical & Environmental Engineering from Brown University, USA (2016-2021) 🎓, where they conducted research under the guidance of Andrew A. Peterson 🧑‍🔬. Their academic journey began with a Bachelor of Technology (B. Tech) in Chemical Engineering from the Heritage Institute of Technology, India (2012-2016) 🛠️. With a strong foundation in chemical engineering, they have pursued advanced studies focusing on environmental solutions and sustainability 🌍. Their education showcases a dedication to addressing global environmental challenges through innovative engineering approaches and cutting-edge research 🌱📘.

Work Experience

Currently serving as a Senior Scientist in Computational Materials Science at Pfizer Inc. (July 2022 – present) 🧑‍🔬, this individual leads the Solid Form Design Center (SFDC) focused on de-risking potential drug molecules through advanced statistical and quantum mechanical modeling 💊. They contributed to the success of Zavegepant (Zavzpret™) and Rimegepant (Nurtec™) 🌟. As a core member of the Crystal Structure Prediction team, they specialize in electronic structure theory, density functional theory, and atomistic modeling 🧬. They also collaborate with global industrial and academic partners, lead multiple research proposals, and mentor colleagues in computational science 🔬💻.

Selected conference presentations

Sharma has delivered numerous invited talks and presentations globally 🌍. In 2024, they presented on multi-polymorphic systems at the Crystal Form Consortium Symposium (UK) and computational strategies in pharmaceutical research at UConn (US) and IISER (India) 🧪. Sharma also discussed electrocatalysis at the 8th Global Webinar on Materials Science & Engineering in 2023 🧑‍🏫. Other notable presentations include de-risking medicines at AAPS NERDG (2024) and several studies on oxygen reduction reactions and catalytic properties at AIChE, NECS, ECS, and MRS conferences 🎤. Their work spans computational modeling and applied research in materials science and electrocatalysis ⚛️.

Research Focus

The research focus of Sharma spans electrochemistry, catalysis, and materials science. Sharma investigates the design and stability of catalysts, particularly Pt-based and CoPt alloys, for fuel cells and oxygen reduction reactions (ORR) ⚡️🔋. His work includes dynamic stability, reaction barriers, and potential-controlled reactions, using advanced techniques like density functional theory (DFT) and experimental-theoretical integration. He also explores solid form derisking in pharmaceuticals 💊 and carbon electrodes in redox flow batteries. Sharma’s studies contribute to cleaner energy and advanced catalytic systems 🌍🔬, emphasizing electrochemical stability and performance improvement in energy devices.

 

Publication Top Notes

Hard-magnet L10-CoPt nanoparticles advance fuel cell catalysis

Anisotropic Strain Tuning of L10 Ternary Nanoparticles for Oxygen Reduction

Face-centered tetragonal (FCT) Fe and Co alloys of Pt as catalysts for the oxygen reduction reaction (ORR): A DFT study

Ordered CoPt oxygen reduction catalyst with high performance and durability

Metal dissolution from first principles: Potential-dependent kinetics and charge transfer

Assessment of carbon monoxide exposure in roadside food-vending shanties using coal cookstoves in Kolkata, India

Dynamic stability of Pt-based alloys for fuel-cell catalysts calculated from atomistics

Conclusion

Dr. Shubham Sharma’s innovative research in computational modeling and materials science, alongside his leadership in both academic and industrial collaborations, makes him an exceptional candidate for the Best Researcher Award. His contributions have not only advanced pharmaceutical drug design but also impacted renewable energy research, marking him as a distinguished leader in his field.

Nagavendra Kommineni | Pharmacology Award | Best Researcher Award


Warning: Undefined variable $insensitive in /home/u792129758/domains/sciencefather.com/public_html/academicawards/wp-content/plugins/internal-link-building-plugin/internal_link_building.php on line 201

Warning: Undefined variable $insensitive in /home/u792129758/domains/sciencefather.com/public_html/academicawards/wp-content/plugins/internal-link-building-plugin/internal_link_building.php on line 202

Dr. Nagavendra Kommineni | Pharmacology Award | Best Researcher Award

Dr. Nagavendra Kommineni, Center for Biomedical Research, Population Council, United States

Dr. Nagavendra Kommineni, Ph.D., is a pharmaceutical scientist specializing in formulation development 🧪. With a background from NIPER-Hyderabad, India, he has expertise in designing innovative drug formulations, particularly in topical and transdermal delivery systems 🩺. His work spans nanoparticle-based platforms and sterile manufacturing processes for injectables. Currently a Postdoctoral Research Fellow in New York, he focuses on translational formulations for sexual and reproductive health, including freeze-dried protein formulations and fast-dissolving tablets 🌱. Dr. Kommineni is adept in analytical techniques and actively contributes to GLP and GMP manufacturing standards.

 

Publication Profile

Education

Dr. Nagavendra Kommineni holds a Ph.D. in Pharmaceutical Sciences from NIPER-Hyderabad, India (2015-2019). He also earned an M.S (Pharm) in Pharmaceutical Sciences (2012-2014) and a Bachelor of Pharmacy degree from Bapatla College of Pharmacy, India (2008-2012).

Work Experience 🏥

As a Postdoctoral Research Fellow in New York, he pioneers translational formulations for sexual and reproductive health, overseeing formulation development, GLP toxicity studies, and GMP manufacturing. He leads projects on freeze-dried protein formulations and fast-dissolving tablets for HIV and contraception.

 

Research Focus

Dr. Nagavendra Kommineni’s research primarily focuses on advanced drug delivery systems 🚀, particularly liposomal formulations, nanocarriers, and depot microspheres for targeted therapy. He explores the potential of exosomes and dendrimers in drug delivery, aiming to enhance therapeutic efficacy while minimizing side effects 🎯. His investigations extend to the development of novel formulations for cancer therapy, psoriasis treatment, and overcoming drug resistance in diseases like breast cancer. Through his work, Dr. Kommineni contributes significantly to the advancement of pharmaceutical science, with a particular emphasis on improving patient outcomes through innovative delivery strategies.